READ

Concordium And Swvl Announce Partnership For Blockchain-Based Mass Transit Systems

Retrieved on: 
星期三, 八月 11, 2021
F-4, PARTIES, News, Calendar, Holding, Prospectus, U.S. Securities and Exchange Commission, Probability, Risk, THE, WHEN, Queen's Gambit, Securities Exchange Act of 1934, Time, Forward-looking statement, Public, Sale, COVID-19, Corruption, READ, Compliance, Privacy, Section 14 of the Canadian Charter of Rights and Freedoms, SPAC, Securities Act of 1933, Failure, Nasdaq, Transport, Sustainability, SEC, B2G, Name, Form F-4, Communication, Form, Security (finance)

Swvl has built a parallel mass transit system offering intercity, intracity, B2B and B2G transportation in 10 megacities across Africa, Asia, and the Middle East.

Key Points: 
  • Swvl has built a parallel mass transit system offering intercity, intracity, B2B and B2G transportation in 10 megacities across Africa, Asia, and the Middle East.
  • The transaction is expected to accelerate its long-term growth strategy and expansion into 20 countries across five continents by 2025.
  • These statements are based on the current expectations of Swvl and/or Queen's Gambit's management and are not predictions of actual performance.
  • However, while Swvl may elect to update these forward-looking statements in the future, Swvl specifically disclaims any obligation to do so.

New CAP Guideline Improves Diagnoses of Patients with Monoclonal Gammopathies

Retrieved on: 
星期二, 八月 10, 2021
General Health, Health, Science, Research, Oncology, American Society for Clinical Pathology, Pathology, International Myeloma Foundation, FAQ, Patient, Association, MGS, Diagnosis, ASCP, Guideline, AACC, Monoclonal gammopathy, College, Serum protein electrophoresis, American Association for Clinical Chemistry, Software, CAP, Marie Cassidy, READ, American Association, ASH, Society, SPEP, MGUS, Laboratory, Archives of Pathology & Laboratory Medicine, Medical laboratory, Medical device, Medicine

The College of American Pathologists (CAP) new evidence-based clinical practice guideline, Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies, establishes recommendations that pathologists and clinicians can implement to better manage testing and improve the accurate diagnoses of patients with monoclonal gammopathies (MGs).

Key Points: 
  • The College of American Pathologists (CAP) new evidence-based clinical practice guideline, Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies, establishes recommendations that pathologists and clinicians can implement to better manage testing and improve the accurate diagnoses of patients with monoclonal gammopathies (MGs).
  • The guideline was published August 4, 2021, as an early online release in Archives of Pathology & Laboratory Medicine.
  • MGs encompass a wide variety of patient conditions that can range in severity from the asymptomatic Monoclonal Gammopathy of Undetermined Significance (MGUS) to the potentially life-threatening Multiple Myeloma.
  • To help the medical community implement the guideline, the CAP provides related resources, including a summary of recommendations, a teaching presentation, FAQs, and an algorithm, available at no cost on cap.org .